New drug lorigerlimab takes on Platinum-Resistant ovarian cancer
NCT ID NCT06730347
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a drug called lorigerlimab in about 80 people with advanced ovarian or clear cell gynecologic cancers that have stopped responding to platinum chemotherapy. Lorigerlimab is a bispecific antibody designed to activate the immune system against tumors. Researchers will measure how many participants' tumors shrink and monitor side effects closely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lorigerlimab (a bispecific antibody that targets PD-1 and CTLA-4 to help the immune system fight cancer)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat ovarian and clear cell gynecologic cancers.
What could go wrong
This is a small, early-phase trial (80 people) with no control group, so results may not apply broadly. The drug can cause immune-related side effects, and many experimental cancer drugs fail to show enough benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gangnam Severance Hospital
RECRUITINGSeoul, 06273, South Korea
Contact
Contact
-
Korea University Guro Hospital
RECRUITINGSeoul, 08308, South Korea
Contact
Contact
-
McGill University
RECRUITINGMontreal, Quebec, H4A3J1, Canada
Contact
Contact
-
National Cancer Center
RECRUITINGGoyang-si, Gyeonggi-do, 410-763, South Korea
Contact
Contact
-
Ochsner MD Anderson Cancer Center
RECRUITINGNew Orleans, Louisiana, 70115, United States
Contact
Contact
-
Princess Margaret Cancer Center
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact
Contact
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
Contact
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact
-
Samsung Medical Center
RECRUITINGSeoul, 135-710, South Korea
Contact
Contact
-
Seoul National University Hospital
RECRUITINGSeoul, 110-74, South Korea
Contact
Contact
-
Seoul National University Hospital Bundang Hospital
RECRUITINGSeongnam-si, Gyeonnggi-Do, 463-707, South Korea
Contact
Contact
-
The University of Texas MD Anderson Cancer Center, Gynecologic Oncology Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact
-
West Penn Allegheny Health
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
Contact
Contact
-
Wisconsin Institute Medical Research- UW Cancer Connect
RECRUITINGMadison, Wisconsin, 53705, United States
Contact
Contact
-
Yonsei University Health System Severance Hospital
RECRUITINGSeoul, 03722, South Korea
Contact
Contact